Diverse Biotech
A disruptive cannabinoid approach to oncology treatment
Presenter: Stella Vnook
Monday, February 10, 2020
Embassy Suites, Chesterbrook, Pennsylvania (directions) |
About
|
Diverse biotech is a US-based biopharmaceutical research company, inventing life-saving therapeutics through novel technology. We are developing innovative therapeutics from a proprietary and patented conjugate synthesis platform (CuSP™), a core foundation relying on synthetic cannabidiol (CBD), creating potentially more efficacious, less toxic entities (NCE's) targeting oncology first, followed by anti-infectives and dermatology. Cannabidiol has been shown to have antineoplastic, anti-inflammatory, and antibacterial effects that have been largely unrealized through rigorous clinical development. We are a growing biopharm company actively seeking an early funding round to continue progression of our R&D program.
Customer problem:
Many chemotherapeutic agents are known to work, however in many cases they are too toxic for patients to complete their cancer therapy. Our innovative, proprietary (CuSP™) technology focuses on the ability to create multiple new chemical entities targeting the most difficult to treat cancers with a disruptive synthetic cannabinoid foundation. This may allow previous, time-tested therapies to be more efficacious and less toxic.
Products/services:
We have begun preclinical work on our initial synthesized conjugates. This will involve several steps, such as in-vitro and in-vivo clinical work, to determine if the conjugated molecules have the desired effects on diseased and normal (control) tissues. The clinical development program goals are that these conjugates will work better than the original molecules in combating difficult to treat cancer with fewer side effects for patients.
Target market:
Our key focus, and exit strategy, will be to partner or license our technology to other pharma/biotech companies who are fully invested in specifically aligned oncology programs and can support the clinical development prior to, or during, Phase 1 trials. Our end customers are ultimately patients suffering with cancer, through the skilled care of medical oncologists, gynecologic oncologists, pediatric oncologists, and supporting staff.
3 Major Issues
|
- We are in two very interesting spaces, CBD and oncology. How can we best position ourselves as a true disruptive biopharm oncology company, but capitalize on the huge interest and investments in the CBD area?
- Being a smaller biopharm and moving our core operations to the tri-state area, particularly PA, how can we best capitalize on the life-sciences ecosystem in this area, such as establishing potential pharma partnerships/collaborations, increasing our overall awareness and leveraging fundraising networks?
- We have a platform technology that we feel is extremely versatile and dynamic. Our initial focus is on oncology, where there is a huge unmet need and we are still striving to develop a new standard of care for patients. How and when should we emphasize to people/investors/pharma partners that we have a platform that can be used in other areas (anti-infectives, derma, etc.)? We are very focused currently on oncology and do not want to be perceived as too broad given our current stage.
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
7:45 - Stella Vnook, CEO of Diverse Biotech, will deliver "Elevator" Pitch to the Group
8:00 - A Panel will address three major issues crucial to helping the Company reach the next level.
9:00 - Open discussion: members and guests
|
 |
Reserve your spot for this special event online now though PayPal.
Please note: You do not need a PayPal account to reserve your spot, most credit cards are accepted.
|
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
None available at this time
|
|
|
